Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Budde

Showing results (101-110 of 155) with videos related to

Pageof 16
Sort By:
Transplant International : Official Journal of the European Society for Organ Transplantation|July 17, 1998
The quality of life in end stage renal disease careJ Waiser, K Budde, M Schreiber, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 9, 2000
FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanismT Böhler, J Waiser, M Schütz, et al.
Transplantation Proceedings|October 8, 2003
Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptorD Dragun, J H Bräsen, C Schönemann, et al.
Transplantation Proceedings|September 19, 2006
Effect of mycophenolate mofetil monotherapy on T-cell functions and inosine monophosphate dehydrogenase activity in patients undergoing a kidney transplantationN Kamar, P Glander, J Nolting, et al.
Transplantation Proceedings|December 23, 2018
Impact of Pre-existing Comorbidities on Long-term Outcomes in Kidney Transplant RecipientsA Kleinsteuber, F Halleck, D Khadzhynov, et al.
Clinical Nephrology|August 31, 2006
Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic)K Budde, G Knoll, J Curtis, et al.
Infection|August 30, 2014
Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patientsP Nickel, M Schürmann, H Albrecht, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 15, 2017
Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal TransplantationN Lachmann, M Niemann, P Reinke, et al.
Transplantation Proceedings|September 2, 1998
Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus diseaseJ Waiser, K Budde, M Schreiber, et al.
Transplantation Proceedings|June 24, 1998
Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 monthsK Budde, L Fritsche, S Smettan, et al.
Pageof 16

Showing results (101-110 of 155) with videos related to

Sort By:
Pageof 16
Transplant International : Official Journal of the European Society for Organ Transplantation|July 17, 1998
The quality of life in end stage renal disease careJ Waiser, K Budde, M Schreiber, et al.
Transplant International : Official Journal of the European Society for Organ Transplantation|December 9, 2000
FTY 720A mediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanismT Böhler, J Waiser, M Schütz, et al.
Transplantation Proceedings|October 8, 2003
Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptorD Dragun, J H Bräsen, C Schönemann, et al.
Transplantation Proceedings|September 19, 2006
Effect of mycophenolate mofetil monotherapy on T-cell functions and inosine monophosphate dehydrogenase activity in patients undergoing a kidney transplantationN Kamar, P Glander, J Nolting, et al.
Transplantation Proceedings|December 23, 2018
Impact of Pre-existing Comorbidities on Long-term Outcomes in Kidney Transplant RecipientsA Kleinsteuber, F Halleck, D Khadzhynov, et al.
Clinical Nephrology|August 31, 2006
Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic)K Budde, G Knoll, J Curtis, et al.
Infection|August 30, 2014
Clindamycin-primaquine for pneumocystis jiroveci pneumonia in renal transplant patientsP Nickel, M Schürmann, H Albrecht, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|June 15, 2017
Donor-Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes Independently Predicts the Incidence of De Novo Donor-Specific HLA Antibodies Following Renal TransplantationN Lachmann, M Niemann, P Reinke, et al.
Transplantation Proceedings|September 2, 1998
Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus diseaseJ Waiser, K Budde, M Schreiber, et al.
Transplantation Proceedings|June 24, 1998
Tacrolimus rescue therapy in late rejection after renal transplantation: outcome after 18 monthsK Budde, L Fritsche, S Smettan, et al.
Pageof 16